Compare GMM & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GMM | VNRX |
|---|---|---|
| Founded | 2017 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.8M | 31.9M |
| IPO Year | 2022 | 2012 |
| Metric | GMM | VNRX |
|---|---|---|
| Price | $1.21 | $0.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 165.7K | ★ 1.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,233,511.00 |
| Revenue This Year | N/A | $60.84 |
| Revenue Next Year | N/A | $404.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 59.10 |
| 52 Week Low | $0.94 | $0.17 |
| 52 Week High | $4.75 | $0.94 |
| Indicator | GMM | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 38.64 |
| Support Level | $1.04 | $0.17 |
| Resistance Level | $3.18 | $0.33 |
| Average True Range (ATR) | 0.15 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 20.99 | 33.37 |
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital asset development for the metaverse industry. The Company leverages its proprietary Mofy Lab technology platform, which integrates three-dimensional (3D) reconstruction technology and artificial intelligence (AI) interactive technology, to create high-definition virtual versions of physical world objects, including humans, animals, and scenes. It provides comprehensive technology solutions to support virtual content production for use across movies, television series, animation, advertising, and gaming. The Company operates through Virtual Technology Services, which generates the majority of revenue, and Digital Asset Development and others.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.